Warsaw - Delayed Quote PLN

Molecure S.A. (MOC.WA)

5.92
-0.09
(-1.50%)
As of 3:50:54 PM GMT+2. Market Open.
Currency in PLN All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0.10
0
0.40
Cost of Revenue
3,317.38
3,409.01
4,101.71
1,634.57
2,773.49
Gross Profit
-3,317.38
-3,409.01
-4,101.61
-1,634.57
-2,773.09
Operating Expense
27,273.61
28,893.16
28,026.44
15,352.84
10,991.21
Operating Income
-30,590.99
-32,302.17
-32,128.05
-16,987.40
-13,764.30
Net Non Operating Interest Income Expense
1,001.04
1,031.16
4,297.16
1,792.95
-6.47
Pretax Income
-29,633.41
-31,287.93
-28,373.12
-15,263.70
-13,636.32
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-29,633.41
-31,287.93
-28,373.12
-15,263.70
-13,636.32
Diluted NI Available to Com Stockholders
-29,633.41
-31,287.93
-28,373.12
-15,263.70
-13,636.32
Basic EPS
-1.40
-1.55
-1.69
-1.09
-0.98
Diluted EPS
-1.40
-1.55
-1.69
-1.09
-0.98
Basic Average Shares
21,045
20,203.20
16,836
14,030
13,951.57
Diluted Average Shares
21,045
20,203.20
16,836
14,030
13,955.90
Total Operating Income as Reported
-30,590.99
-32,302.17
-32,128.05
-16,987.40
-13,764.30
Total Expenses
30,590.99
32,302.17
32,128.15
16,987.40
13,764.70
Net Income from Continuing & Discontinued Operation
-29,633.41
-31,287.93
-28,373.12
-15,263.70
-13,636.32
Normalized Income
-29,633.41
-31,287.93
-28,373.12
-15,263.70
-13,636.32
Interest Income
1,097.16
1,125.39
4,389.73
1,911.22
0
Interest Expense
0.02
0.09
0
16.36
6.24
Net Interest Income
1,001.04
1,031.16
4,297.16
1,792.95
-6.47
EBIT
-29,633.38
-31,287.84
-28,373.12
-15,247.34
-13,630.08
EBITDA
-25,770.75
-27,468.05
-24,493.03
-13,934.19
-13,330.27
Reconciled Cost of Revenue
3,317.38
3,409.01
4,101.71
1,634.57
2,773.49
Reconciled Depreciation
3,862.64
3,819.79
2,826.16
1,313.16
299.82
Net Income from Continuing Operation Net Minority Interest
-29,633.41
-31,287.93
-28,373.12
-15,263.70
-13,636.32
Normalized EBITDA
-25,770.75
-27,468.05
-24,493.03
-13,934.19
-13,330.27
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 4/19/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RVU.WA Ryvu Therapeutics S.A.
29.30
-3.95%
 
BCX.WA Bioceltix S.A.
113.20
-0.70%
 
PTCT PTC Therapeutics, Inc.
51.58
-0.31%
 
RGNX REGENXBIO Inc.
10.29
+4.89%
 
RCKT Rocket Pharmaceuticals, Inc.
3.2608
+3.19%
 
PHAT Phathom Pharmaceuticals, Inc.
9.17
+2.18%
 
KLTO Klotho Neurosciences, Inc.
1.4195
-29.38%